Last reviewed · How we verify
Calbogen — Competitive Intelligence Brief
phase 2
hexcarbacholine
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Calbogen (HEXCARBACHOLINE). Calbogen works by stimulating the parasympathetic nervous system, which helps to regulate various bodily functions such as heart rate and digestion.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Calbogen TARGET | HEXCARBACHOLINE | phase 2 | hexcarbacholine |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (hexcarbacholine class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Calbogen CI watch — RSS
- Calbogen CI watch — Atom
- Calbogen CI watch — JSON
- Calbogen alone — RSS
- Whole hexcarbacholine class — RSS
Cite this brief
Drug Landscape (2026). Calbogen — Competitive Intelligence Brief. https://druglandscape.com/ci/hexcarbacholine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing